Positive data for intrathecally delivered Zolgensma could broaden its patient population

The latest data on Novartis’ Zolgensma could help solidify and possibly expand the gene therapy’s position in the SMA market as the company prepares for a potential new entrant in the coming months.

During a virtual Clinical Trial Session conducted by the Muscular Dystrophy Association on Tuesday, the AveXis Inc. unit of Novartis AG (NYSE:NVS; SIX:NOVN) presented data from four trials including one that supports use of the therapy in a broader population of spinal muscular atrophy (SMA) patients and one that supports its long-term durability...